References
Figure legends
Figure 1: Characteristics of SARS-coV-2 infected lungs and A549 cells. Gene Set Enrichment Analysis (GSEA) of genes modulated in A) SARS-coV-2 infected lung and B) A549 cells. C) Transcription factor enrichment of genes up-regulated in SARS-coV-2 infection. D) Genes activated in SARS-coV-2 overlapping with genes down-regulated upon kinase perturbations. Up-regulated genes mapped to their transcription factors and kinases in E) SARS-coV-2 lung and F) A549 cells.
Figure 2: Effect of Thalidomide and Lenalidomide on Immune System. GSEA network of gene expression profiles of A) thalidomide and B) lenalidomide treated A549 cells. C) Activities of kinase involved in immunomodulation and MAPK signaling in the presence of thalidomide D) Biological Pathways enriched by kinases affected by thalidomide.
Figure 3: A) GO Biological Process enrichment comparison of gene expression signatures B) SARS-coV-2 infected tissues B) Overexpression of immune response genes in SARS-coV-2 tissues and suppression by thalidomide and lenalidomide C) B cell receptor signaling activated in PBMC of SARS-coV-2 patient and T cell activation in SARS-coV-2 lungs D) Modulation of ERK1 and ERK2 cascade in SARS-coV2 lung and thalidomide in A549.
Figure 4: Activation of A) inflammation, B) TLR signaling, C) NOD-like signaling, D) Osteoblast differentiation and E) Cytokine signaling in SARS-coV-2 and genes targeted by thalidomide and lenalidomide in the signaling pathways.
Figure 5: Viral life cycle and defense response to virus. A) Up-regulation of pathways pertaining to viral entry, life cycle and antiviral response was observed in SARS-coV-2 infected lungs, PBMC, BALF and A549 cells and their modulation by thalidomide and lenalidomide. Overexpression of genes implicated in B) Interferon signaling and C) Type I interferon signaling in SARS-coV-2 infected lung and A549.
Figure 6: A) Similarity of SARS-coV-2 signatures with disease-specific phenotypes. Differentially modulated genes in SARS-coV-2 and thalidomide treatment similar to profiles of B) lymphoma and D) Multiple Myeloma. C) Overlapping of SARS-coV-2 expression profile of SARS-coV-2 affected lung with systemic lupus erythematosus.